miércoles, 7 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 26, 2026

AGNC (AGNC) Q2 2025 Earnings Call Transcript

View original at finance.yahoo.com
AGNC (AGNC) Q2 2025 Earnings Call Transcript Image source: The Motley Fool. Date Tuesday, July 22, 2025 at 8:30 a.m…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Marginal investments are expected to generate high teens returns, somewhere between 18% to 20%

    80% confidence
  • Federal Reserve quantitative tightening expected to end relatively soon, possibly through year-end 2025

    80% confidence
  • Net spread and dollar roll income expected in range of mid- to high $0.30s to low to mid-$0.40s per share

    80% confidence
  • The U.S. government will maintain implicit guarantees for Fannie Mae and Freddie Mac during privatization

    80% confidence
  • The outlook improved in Q2 2025 due to manageable MBS supply, growing MBS demand, stabilizing spreads at cheap levels, and cautious GSE reform approach

    80% confidence
  • Expected MBS net supply for 2025 is approximately $200 billion at the low end of forecasts

    80% confidence
  • AGNC has the lowest operating costs in the industry at 111 basis points

    80% confidence
  • AGNC has no plans to grow for the sake of growing; growth is tied to accretive capital raising

    80% confidence
  • GSE privatization must not widen mortgage spreads and should potentially tighten them

    80% confidence
  • GSE reform will follow a do-no-harm approach with no upward pressure on mortgage rates

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com
AGNC (AGNC) Q2 2025 Earnings Call Transcript — Source | Via News | es.VIA.NEWS